Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 5, 2001, Pages 415-424

  Yao, Caiping ^a   Kunze, Kent L ^a   Kharasch, Evan D ^a   Wang, Yi ^a   Trager, William F ^a   Ragueneau, Isabelle ^a   Levy, RenéH ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLURIC ACID; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; FLUVOXAMINE MALEATE; THEOPHYLLINE;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIVER MICROSOME; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUVOXAMINE; HUMANS; THEOPHYLLINE;

EID: 0035215519     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.119724     Document Type: Article

References (34)

1. A fluvoxamine-caffeine interaction study
2. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline
3. Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo
4. Fluvoxamine-clozapine drug interaction: Inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism
5. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine
6. Effect of inhibitor depletion on inhibitory potency: Tight binding inhibition of CYP3A by clotrimazole
7. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants
8. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-20 inducible cytochrome(s) P-450 in human liver microsomes
9. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation
10. Species differences in the transport activity for organic anions across the bile canalicular membrane
11. Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: Detection of 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate
12. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation
13. Determination of theophylline metabolites in human liver microsomes by high-performance liquid chromatography
14. Determination of theophylline and its metabolites in human urine and plasma by high-performance liquid chromatography
15. High performance liquid chromatography with ultraviolet detection used for laboratory routine determination of fluvoxamine in human plasma
16. Kinetics of drug metabolism inhibition: Use of metabolite concentration-time profiles
17. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat
18. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction
19. Kinetics of drug-drug interactions
20. Clinical pharmacokinetics of fluvoxamine
21. Metabolism of theophylline by cDNA-expressed human cytochromes P-450
22. Clinical pharmacokinetics of theophylline
23. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine
24. In vitro prediction of the terfenadineketoconazole pharmacokinetic interaction
25. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver
26. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver
27. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitroin vivo correlations
28. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
29. Microsomal binding of amitriptyline: Effect on estimation of enzyme kinetic parameters in vitro
30. Prediction of pharmacokinetic drug/drug interactions from in vitro data: Interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants
31. Nonspecific binding of drugs to human liver microsomes
32. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy
33. Fluvoxamine-clozapine dose-dependent interaction
34. Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats